Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities: 2024

Historic Total Non-Current Liabilities for Krystal Biotech (KRYS) over the last 1 years, with Dec 2024 value amounting to $108.0 million.

  • Krystal Biotech's Total Non-Current Liabilities rose 3.52% to $99.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.1 million, marking a year-over-year increase of 3.52%. This contributed to the annual value of $108.0 million for FY2024, which is N/A change from last year.
  • Per Krystal Biotech's latest filing, its Total Non-Current Liabilities stood at $108.0 million for FY2024.
  • Krystal Biotech's Total Non-Current Liabilities' 5-year high stood at $108.0 million during FY2024, with a 5-year trough of $108.0 million in FY2024.
  • Moreover, its 1-year median value for Total Non-Current Liabilities was $108.0 million (2024), whereas its average is $108.0 million.